When people ask about GLP-1 receptor agonists and bone density, one of the first surprises is how little the large weight-loss trials actually set out to measure. The major clinical programs — the ones most discussed in news coverage — were designed around body weight, blood sugar, and cardiovascular markers. Bone mineral density was not on their list.
Research into bone health during GLP-1 receptor agonist treatment has grown since then. Dedicated studies have followed people taking these medications and specifically measured bone outcomes. What those measurements show — and what remains unanswered — is what this article covers.
Why Weight Loss and Bone Density Are Linked
To understand what trials found, it helps to understand why weight and bone are connected in the first place.
Bone is not a fixed structure. It is constantly being built up by cells called osteoblasts and broken down by cells called osteoclasts, in a process called bone remodeling. One signal that influences how much bone is maintained is mechanical loading — the force that body weight places on the skeleton during daily movement. Heavier bodies, under typical conditions, may place more loading demand on bones. Research suggests this can be a stimulus for bone maintenance.
When significant weight is lost, that loading force decreases. This pattern has been observed across many forms of weight reduction — not only with GLP-1 receptor agonists. Studies of bariatric surgery and sustained caloric restriction have described similar changes in bone density over time. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) notes that “excessive dieting or poor protein intake may increase your risk for bone loss” and that “low levels of physical activity and prolonged periods of inactivity can contribute to an increased rate of bone loss.”
This context matters because it shapes how researchers interpret data from GLP-1 receptor agonist studies. When bone density changes are observed, the question researchers ask is whether the pattern resembles what caloric restriction alone would produce, or whether it reflects something distinct about this class of medication.
Separately, significant weight loss can also involve changes in muscle mass. Because muscle and bone interact mechanically — muscle contractions place force on bone during movement — some researchers and providers consider muscle and bone health together when evaluating the effects of sustained weight loss. For more on the muscle side of this conversation, the evidence on muscle loss during GLP-1 treatment is covered here.
What the Major Trials Were Designed to Measure
The STEP program — a series of large phase 3 randomized controlled trials evaluating semaglutide for weight management in adults with overweight or obesity — produced some of the most-cited data on GLP-1 receptor agonists. STEP 1, authored by Wilding et al. and published in the New England Journal of Medicine in 2021, enrolled participants and tracked body weight, waist circumference, blood pressure, lipid levels, blood glucose, and quality of life. Bone mineral density was not a pre-specified endpoint.
A 2025 review published in Osteoporosis International by Karam, Mabilleau, and Paccou examined this gap directly, noting that “none of the published [STEP] studies have provided information on fracture-related outcomes.” This means the foundational semaglutide weight-loss trials do not tell researchers — or patients — what happened to bone health in study participants over the course of treatment.
The absence of bone data from the STEP trials is a design choice, not a finding. It means researchers interested in bone outcomes have had to look elsewhere — to smaller, dedicated studies that specifically set out to measure them.
The table below shows how different types of studies have approached the question of GLP-1 receptor agonists and bone health, and what each was designed to capture.
| Study Type | Primary Goal | Bone Endpoints Included | What Was Measured |
|---|---|---|---|
| STEP weight-loss trials | Body weight reduction | No | Weight, cardiometabolic markers, quality of life |
| Dedicated bone outcome studies | Bone response to GLP-1 treatment | Yes | BMD by DXA and REMS, bone turnover markers, trabecular bone score |
| Cardiovascular outcome trials | CV event reduction | Safety monitoring only | Fracture reports captured as adverse events |
What Dedicated Bone Studies Found
Bone Mineral Density Changes in Clinical Studies
One of the more thorough dedicated bone studies in this area is a 12-month longitudinal study published in Calcified Tissue International in 2024. Al Refaie and colleagues enrolled 54 people with type 2 diabetes who were beginning GLP-1 receptor agonist therapy — either dulaglutide or semaglutide — and followed them for a year, measuring bone at the lumbar spine, femoral neck, and total hip.
The researchers used two different imaging methods: dual-energy X-ray absorptiometry (DXA), the most commonly used technique for bone density measurement, and radiofrequency echographic multispectrometry (REMS), a newer approach. They also measured bone turnover markers and the trabecular bone score (TBS), which reflects the internal structural organization of bone rather than just its mineral density.
Bone mineral density reductions were observed at the lumbar spine and hip over the 12 months. The DXA-based measurement captured a larger reduction than the REMS-based measurement. The difference reflects how these two techniques assess slightly different aspects of bone tissue. However, the trabecular bone score — the measure of structural organization — showed only marginal change. The study authors concluded that “a 1-year treatment with GLP-1RAs is capable of reactivating bone turnover and preserving bone quality of the spine in patients with T2DM.”
This distinction between bone mineral density and bone quality is worth understanding. Bone density — the measure most people are familiar with — reflects how much mineral is packed into a given area of bone. Bone quality refers to how that mineral is organized structurally. These two things do not always move together, which is why some researchers argue that density alone does not give a complete picture of fracture risk.
The Broader Pattern Across Available Evidence
The 2025 Osteoporosis International review by Karam, Mabilleau, and Paccou drew together evidence from multiple sources to characterize the overall pattern. The review described GLP-1 receptor agonists as producing “modest BMD reduction” that “enhances bone remodeling, favoring resorption similar to the effects of calorie restriction.”
The characterization “similar to the effects of calorie restriction” is significant. It suggests that, based on available evidence, the bone changes observed with GLP-1 receptor agonist treatment may not be fundamentally different from what other methods of substantial weight reduction produce. This does not mean the changes are inconsequential — but it provides context for where the medication-specific signal sits within the broader phenomenon of weight-loss-related bone effects.
The major weight-loss trials were not designed to measure bone density. Dedicated studies that did measure it found modest changes resembling those seen with caloric restriction.
A Signal Researchers Are Watching
Beyond the studies designed specifically to measure bone outcomes, some bone-related data has emerged from large trials structured around other goals.
The SELECT trial was a cardiovascular outcomes study in adults with obesity and established cardiovascular disease who received semaglutide or placebo. The 2025 Osteoporosis International review by Karam, Mabilleau, and Paccou noted that SELECT captured a higher incidence of hip and pelvic fractures among female participants receiving semaglutide compared to those receiving placebo — 1.0% versus 0.2% in that population.
Several important pieces of context surround this finding:
- The SELECT participants had established cardiovascular disease, which may itself influence fracture risk through various mechanisms
- This was a safety signal captured through adverse event reporting, not a pre-specified bone endpoint designed to capture fracture rates systematically
- The absolute numbers are small
- The cause behind the observed difference in fracture rates has not been established
Researchers are continuing to evaluate whether this signal reflects a meaningful pattern across different populations and study designs, and what biological mechanisms might explain it. GLP-1 receptors have been found on osteoblasts and osteoclasts — the cells responsible for bone formation and bone resorption. This has led researchers to investigate whether these medications have direct effects on bone cell activity. The current evidence has not established a clear causal mechanism.
The SELECT finding is something providers who follow this research are aware of. It is a reason the topic of bone health has received more attention in recent years, and why some researchers have called for bone density to be included as a pre-specified endpoint in future large trials.
Physical Activity and Bone During Significant Weight Loss
One of the more consistent threads across bone health research — not just in GLP-1 receptor agonist studies, but in the broader literature on weight loss and bone — is the potential role of physical activity in supporting bone mineral density when body weight is decreasing.
The Osteoporosis International review by Karam, Mabilleau, and Paccou noted that “exercise with liraglutide helps mitigate BMD loss at the hip and lumbar spine.” This finding, from research on liraglutide (a related medication), adds to a body of evidence suggesting that weight-bearing movement during sustained weight loss may help moderate some of the bone density changes that would otherwise occur.
Weight-bearing activity — movement where the body supports its own weight — applies mechanical loading signals to bone that may help stimulate bone formation even as body weight decreases. This is one reason that researchers and providers often discuss the importance of remaining physically active during significant weight loss rather than relying solely on dietary changes.
NIAMS also notes that “low levels of physical activity and prolonged periods of inactivity can contribute to an increased rate of bone loss” — a finding that applies generally and is not limited to people using GLP-1 receptor agonists. Staying active, at whatever level is appropriate for an individual’s health situation, has implications for bone health that go beyond any specific treatment.
What forms of activity are appropriate, and at what level, depends on individual circumstances — including fitness history, joint health, and current treatment stage. That guidance comes from knowing a person’s specific situation, which makes it a conversation for a provider rather than a general article recommendation.
Questions Worth Bringing to Your Provider
None of the evidence reviewed in this article points toward a single action that every reader should take. What it does suggest is that bone health is a topic worth raising with a provider, particularly for people who have been taking a GLP-1 receptor agonist for an extended time, or who have other individual factors that may affect bone health — including age, current physical activity level, nutritional intake, or a personal or family history of bone loss.
If you want to start a conversation, some questions that researchers themselves are actively investigating may serve as a starting point:
- “Is monitoring bone health something that makes sense for my situation as I lose weight?”
- “Are there any signs or symptoms I should be aware of that might indicate bone changes?”
- “Does my activity level or what I’m eating create any particular considerations around bone health?”
- “Is a baseline bone health assessment something you’d consider for someone at my stage of treatment?”
Having specific, documented information about your own experience — how your weight has changed, what your activity levels have been like, any physical changes you have noticed — gives a provider more to work with than a general inquiry. The GLP-1 Side-Effect & Progress Tracker is designed to help you build exactly that kind of record over time.
Separately, if your provider mentions vitamins or nutrients relevant to bone health, a dedicated overview of nutrients commonly discussed in the context of GLP-1 treatment covers that topic directly.
A Note on the Current Evidence
Research on GLP-1 receptor agonists and bone health is evolving. The studies discussed in this article were conducted in specific populations — including people with type 2 diabetes, people at high cardiovascular risk, and people with obesity but not diabetes. Findings from one group may not apply to another, and the field has not yet produced the kind of large, pre-specified bone endpoint trials that would allow more definitive conclusions.
GLP-1 receptor agonists are not approved as treatments for osteoporosis or as bone-protective medications. This article is not suggesting they protect bone or that they predictably harm it — it is describing what the available measurements have shown so far, and where the evidence currently sits.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for professional medical consultation, diagnosis, or treatment. The research described reflects studies in specific populations; individual results vary and findings may not apply to every reader. Do not make changes to your treatment or health routine based on this article alone. Consult a licensed healthcare provider for guidance on your individual situation. If you are experiencing a medical emergency, call 911.